A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1)
Latest Information Update: 06 Nov 2025
At a glance
- Drugs Brenipatide (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Acronyms RENEW-Smk-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 06 Nov 2025 New trial record